Abstract: An article of footwear includes a sole, an upper connected to the sole, and an insole positioned within a foot cavity. The upper includes an outer shell extending from the heel region to the forefoot region, the outer shell including an outer heel wall defining an upper perimeter. A bootie is positioned within the outer shell and extends from the heel region to the forefoot region. The bootie is free floating relative to the outer shell within the heel region. The booting includes an inner heel cup configured to be moved between an upright position and a folded position. A posterior wall of the inner heel cup extends above the upper perimeter of the outer heel wall when the inner heel cup is in the upright position. The posterior wall of the inner heel cup is laid against the insole when the inner heel cup is in the folded position.

Abstract: The present invention relates to oxopiperazines that mimic helix ?B of the C-terminal transactivation domain of HIF1?. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1? with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Abstract: The present invention relates to oligooxopiperazines for modulating the p53-Mdm2 interaction. Exemplary oligooxopiperazines include those of Formula IA, Formula IB, and Formula IC below (wherein the various substituents are as defined herein). Methods of using the oligooxopiperazines are also disclosed.

Abstract: The present invention relates to oxopiperazines that mimic helix ?B of the C-terminal transactivation domain of HIF1?. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1? with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Abstract: The present invention relates to oxopiperazines that mimic helix ?B of the C-terminal transactivation domain of HIF1?. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1a with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Abstract: The present invention relates to oxopiperazines that mimic helix ?B of the C-terminal transactivation domain of HIF1?. Also disclosed are pharmaceutical compositions containing these oxopiperazines and methods of using these oxopiperazines (e.g., to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF1a with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, and decrease cell survival and/or proliferation).

Abstract: The present invention relates to oligooxopiperzines for modulating the p53-Mdm2 interaction. Methods of using the oligooxopiperazines are also disclosed.

Abstract: The disclosure describes a system in which medical devices, such as external defibrillators, vital signs monitors, or computers, collect medical event information during the treatment of a patient, and transmit the medical event information to a data destination, e.g., a computer at hospital or other medical facility. The system includes a remote server that stores data destination information for one or more data destinations, and transmits the data destinations information to the medical devices via a network. A medical device transmits medical event information to a data destination according to the data destination information that was received from the server for that destination. The data destination information for a particular destination may include, for example, information indicating a communication medium, a communication protocol, a telephone number, a network address, a network name, or login information used by a medical device to communicate with the destination.

Abstract: An electrolytic reduction cell for the production of metal is provided, in which liquid metal is deposited at or adjacent an upper surface of a cathode. The electrolytic reduction cell includes an anode structure and a cathode located beneath the anode structure, wherein an upper portion of the cathode comprises an aggregate of particles sized and shaped such that in operation of the cell liquid metal is present in at least an upper part of the aggregate and a slurry of liquid metal and particles is established, the slurry comprising a substantially uniform dispersion of the particles in a continuous liquid phase of the liquid metal, the slurry having a viscosity sufficiently high such that under operating conditions of the cell the slurry is relatively immobile. Methods for the production of a metal by electrolysis in the electrolytic cell are also provided.